Impact of cannabidiol on anxiety disorders: systematic review of RCTs

Introduction and clinical context

The study Impact of cannabidiol on anxiety disorders: systematic review of RCTs (Life (MDPI) · 2024) is part of the scientific research on the use of cannabinoids in anxiety and sleep.

Cannabidiol (CBD) is widely investigated for anxiety disorders and sleep disorders. Case series and clinical trials suggest a reduction in anxiety symptoms and an improvement in sleep quality in some patients, with a generally favorable tolerability profile. Among the proposed mechanisms are the modulation of serotonergic receptors and of the endocannabinoid system. The response is individual, and the dose should be adjusted with medical follow-up.

Understanding what science shows about the use of cannabinoids in anxiety and sleep helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Review of randomized controlled trials on CBD in anxiety disorders. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

Cannabidiol exerts an anxiolytic effect mainly through the modulation of serotonergic receptors (5-HT1A) and of the endocannabinoid system, with a possible action on sleep by reducing hyperarousal. It is generally well tolerated, but can cause drowsiness, fatigue and appetite changes. High doses of THC can, paradoxically, increase anxiety, which reinforces the preference for CBD-rich formulations in this context. Attention is given to drug interactions via the cytochrome P450 pathway. The dose should be individualized and monitored, avoiding self-medication.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Life (MDPI) · 2024). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does CBD help with anxiety?

Studies suggest a reduction in anxiety symptoms in some patients; the response is individual and prescribed by a doctor.

Does CBD improve sleep?

There are reports of improved sleep quality, often associated with reduced anxiety.